Patients with active non-hematologic malignancies (except non-melanoma skin cancers) or those with non-hematologic malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within  years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Platelets >= ,/mcL (>= , for patients with hematologic malignancies)
Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)
Histologically documented metastatic cancer (solid tumors, not including hematologic malignancies)
Participants with hematologic malignancies
Confirmed advanced hematologic malignancies; Phase :
Non-epithelial breast malignancies such as sarcoma or lymphoma.
Hematologic malignancies other than lymphomas.
Hematologic malignancies other than lymphomas.
Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within  years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Current hematologic malignancies.
Natural Killer cell malignancies
Non-epithelial breast malignancies such as sarcoma/lymphoma
Germ cell or hematologic malignancies
Patients with any of the following hematologic malignancies who are considered to be eligible for allogeneic transplantation:
Non-epithelial breast malignancies such as sarcoma or lymphoma
Natural killer cell malignancies
Non epithelial breast malignancies such as sarcoma or lymphoma
Remission of any acute hematologic malignancy or adequate disease control for chronic malignancies
Non-epithelial breast malignancies such as sarcoma or lymphoma
Non-epithelial malignancies such as sarcoma or lymphoma.
Non-epithelial breast malignancies such as sarcoma or lymphoma
Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within  years\r\n* This exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Natural killer cell malignancies
Hematologic malignancies other than lymphomas.
Natural killer cell malignancies
Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within  years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Part : solid tumors or lymphomas, or hematologic malignancies
Diagnosis of any of the following hematologic malignancies:
Patients with active non-hematologic malignancies (except non-melanoma skin cancers); this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Patients with active non-hematologic malignancies (except non-melanoma skin cancers) or those with non-hematologic malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within five years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
have prior or concurrent malignancies, inclusive of hematologic, primary brain tumor, sarcoma, and other solid tumors, unless in complete remission with no therapy for a minimum of  years
Patients with history of hematologic malignancies who have received at least  lines of standard chemoimmunotherapy and have persistent disease
Non-epithelial breast malignancies such as sarcoma or lymphoma
Patients with high risk hematologic malignancies, including those with induction failure and in relapse
Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within  years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Patients with the following hematologic malignancies will be permitted although other diagnoses can be considered if approved by Patient Care Conference (PCC) and the principal investigators:
Patients with active non-hematologic malignancies (except non-melanoma skin cancers) or those with non-hematologic malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within five years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Patients with active non-hematologic malignancies (except non-melanoma skin cancers); this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than  years from the time of complete remission, and have a > % risk of disease recurrence; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Patients with active non-hematologic malignancies (except non-melanoma skin cancers); this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Patients with a history of non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than  years from the time of complete remission, and have a > % risk of disease recurrence; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Concurrent non-hematologic malignancies requiring treatment.
Patients with islet cell tumors or other non-epithelial cell malignancies of the pancreas.
Patients with hematologic malignancies completing a prior idelalisib study with a clinical benefit are eligible
Patients with history of hematologic disease, including myelodysplasia or bone marrow malignancies
Hematologic malignancies including acute and chronic leukemias, myelodysplastic syndromes, and myeloma
Natural Killer Cell Malignancies
Patients with active non-hematological malignancies (except non-melanoma skin cancers) or those with non-hematological malignancies (except non-melanoma skin cancers) who have been rendered with no evidence of disease, but have a greater than % chance of having disease recurrence within  years; this exclusion does not apply to patients with non-hematologic malignancies that do not require therapy
Any of the following hematologic malignancies:
Hematologic malignancies with the exception of lymphoma
Any of the following hematologic malignancies:
Relapsed or progressive advanced malignancies (solid tumors or hematologic malignancies)
